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Abstract: Dry eye disease is a common ocular condition affecting millions of people worldwide.
Artificial tears are the first line therapy for the management of dry eye disease. Artificial tear
formulations contain a variety of active ingredients, biologically active excipients, and preservatives.
Many of these formulations are also available as preservative-free. This study was conducted to
inspect artificial tear formulations currently marketed in the United States for their active ingredients,
biologically relevant excipients, and preservatives. The marketed artificial tears were examined at
various US retail pharmacy chains and using the manufacturers’ website to compile information
about active ingredients, inactive ingredients, and preservatives. The currently marketed artificial
tears can be grouped into four categories based on their active ingredients. The artificial tears also
contain biologically active chemicals listed as inactive ingredients, which have osmoprotectant,
humectant, and tear film lipid layer or mucous layer mimicking properties. Most artificial tears
contain vanishing type preservatives such as purite or sodium perborate and safer quaternary
compound polyquaternium-1. The majority of these artificial tear formulations are also available as
preservative-free single dose unit. The study provides a formulary of artificial tears based on active
ingredients, biologically active excipients, and the preservative-free option. The formulary should
assist healthcare providers in making a stepwise and rational selection of appropriate artificial tears
for patients suffering from dry eye disease.
Keywords: artificial tears; dry eye; demulcents; ophthalmic preservatives; osmoprotectants; humectants
1. Introduction
Dry eye disease is a common ocular condition affecting millions of people all over the
world. According to National Health and Wellness Survey, an estimated 16.4 million people
in the United States suffer from dry eye disease [1]. As per the current Tear Film & Ocular
Surface Society (TFOS) definition, dry eye is a multifactorial disease characterized by loss of
tear film homeostasis, tear hyperosmolarity, ocular surface inflammation, and neurosensory
abnormalities [2]. The condition can cause a wide array of symptoms such as redness,
stringy mucous, burning, and itchy sensation. Left untreated, the disease can result in
visual disturbance and tear film instability with potential damage to the ocular surface [3].
Since the disease can significantly impact professional, social, and leisure activities, it
leads the patient either to self-medicate with over-the-counter products or to seek medical
help. Although the symptoms may improve or worsen over the natural course of the
disease, dry eye disease is considered a lifelong condition [4]. Pharmacological and non-
pharmacological interventions significantly improve the symptoms, however long-term
adherence to these approaches is necessary for the effective management of dry eye disease.
Detailed patient history, clinical examination, and diagnostic tests can play a very important
role in effective management of this multifactorial disease [4]. A thorough clinical workup
can also identify any underlying conditions or systemic diseases contributing to dry eye,
J. Clin. Med. 2021, 10, 1289. https://doi.org/10.3390/jcm10061289 https://www.mdpi.com/journal/jcm
J. Clin. Med. 2021, 10, 1289 2 of 11
since treating these underlying conditions is imperative for the effective management of
dry eye disease [4].
Tear film is composed of a muco-aqueous layer underlying a lipid layer. It contains
oxygen, metabolites, antimicrobials, and proteins [5]. The importance of tear film in
keeping the ocular surface healthy has long been recognized, since it serves to provide
nutrients, moisture, smooth the optical surface as well as helps to remove microbes. Tear
replacement remains one of the mainstay approaches for the treatment of dry eye [4,6].
Although artificial tears are not meant to recapitulate the functions of natural tears, they
do provide remarkable symptomatic and palliative relief in dry eye [4,6]. In 2018, artificial
tears accounted for $2.2 billion in global sales, and their market continues to grow [7].
Healthcare providers play a critical role in guiding patients to choose the most appropriate
artificial tear product. However, recommending the right artificial tear product can be
difficult for many reasons. A vast number of artificial tear products are currently available
in the United States. These artificial tears contain a wide variety of active ingredients and
come in multidose vials with preservative or as preservative-free single dose units. Many
of these artificial tears also contain excipients that are listed under inactive ingredients, but
these excipients are known to contribute to their therapeutic benefits. Despite such a large
variety of artificial tears, there is a paucity of information with up-to-date classification
of marketed artificial tears based on their active and pharmacological relevant inactive
ingredients, as well as their availability with or without preservatives. The aim of this
study was to screen and categorize marketed artificial tear formulations based on their
active ingredients, biologically relevant excipients, and preservatives. The information
should help healthcare providers with the knowledge about which artificial tears they can
initially choose and then switch to the ones with additional biologically active ingredients
or another class with a different active ingredient.
2. Materials and Methods
The marketed artificial tears were surveyed at various US retail pharmacy chains
and using the manufacturers’ website to compile the information about active ingredients,
inactive ingredients, and preservatives. The artificial tear preparations were then tabulated
based on the major active ingredient and the biologically active excipients listed under
inactive ingredients. The type of preservative present in the formulations was noted, and it
was also determined if these formulations were available as preservative-free single dose
application units.
3. Results
3.1. Active Ingredients in Artificial Tears
Artificial tears contain one or more FDA-approved demulcents as active ingredient [8].
FDA defines demulcent as a primarily water-soluble polymer, which is applied topically
to the eye to protect and lubricate mucous membrane surfaces and relieve dryness and
irritation. The list of these demulcents and their concentration range was provided by
the FDA in a 1988 monograph to help reduce the costs and expedite approval of artificial
tears [8]. The FDA approved demulcents include (a) Cellulose derivatives: Carboxymethyl-
cellulose (CMC), Hydroxypropyl methylcellulose (hypromellose), Hydroxyethylcellulose,
Methylcellulose, (b) Dextran 70, (c) Gelatin, (d) Polyols: Glycerin, Polyethylene glycol (300,
400), Polysorbate 80, (e) polymers: Polyvinyl alcohol, Polyvinyl pyrrolidone (povidone).
Our screening data demonstrates that the currently marketed tears contain CMC,
hypromellose, dextran, glycerin, polyethylene glycol 400, polysorbate 80, polyvinyl alcohol,
and povidone as active ingredients (Tables 1–4). However, there are no currently marketed
artificial tears that contain hydroxyethyl cellulose, methylcellulose, gelatin, or polyethylene
glycol 300. CMC is a polysaccharide with mucoadhesive properties and has been shown
to bind to corneal epithelial cells. It enhances tear viscosity and increases the precorneal
residence time of artificial tears at 1% concentration [9]. CMC is the primary active ingredi-
ent in Thera tears® (Akorn Consumer Health, Ann Arbor, MI, USA) and Refresh® brand
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(Allergan, Irvine, CA, USA) of artificial tears, with some formulations of the latter brand
also containing glycerin and polysorbate 80 (Table 1). HPMC, better known as hypromel-
lose, is also a polysaccharide polymer produced from cellulose. Hypromellose helps to
moisten and lubricate the eye surface. Hypromellose along with dextran and glycerin are
the demulcent and humectants in the GenTeal® brand (Alcon, Fort Worth, TX, USA) of
tears (Table 2). Further, our data analysis shows that propylene glycol, polyethylene glycol
400, and glycerin are three main polyol demulcents in currently marketed artificial tears
(Table 3). Propylene glycol and glycerin also act as humectants to retain moisture at the
ocular surface. The Systane® brand (Alcon, Fort Worth, TX, USA) has two formulations:
Systane Balance® and Systane Complete®, with exact identical composition having propy-
lene glycol as the active ingredient. However, these two formulations have significantly
different physicochemical characteristics, with Systane Balance® as microemulsion and Sys-
tane Complete® as a nanodrop formulation [10]. Three other formulations from Systane®
are Original®, Ultra®, and Gel®, which contain propylene glycol plus polyethylene glycol
as active ingredients but differ in their physicochemical properties— especially viscosity
and biological properties—as well despite having a similar composition [10]. Soothe®
drops (Bausch + Lomb, Bridgewater, NJ, USA) also contain both glycerin and propylene
glycol as its active ingredients (Table 3). Oasis® brand drops (Oasis Medical, Inc., Glendora,
CA, USA) and Blink® tears (Johnson & Johnson Vision, Jacksonville, FL, USA) contain
glycerin and polyethylene glycol alone, respectively as demulcent (Table 3).
Table 1. Artificial tears containing Carboxymethylcellulose (CMC) as a demulcent.
Active Ingredient(s) Inactive Ingredients with
Biological Activity
Brand
With Preservative Preservative Free
CMC 0.25% Thera Tears® (Dequest) Thera Tears®
CMC 0.25% Trehalose Thera Tears Extra® (Dequest)
CMC 0.5% Refresh Tears® (Purite) Refresh Plus®
CMC 0.5% Glycerin 0.9% Erythritol L-Carnitine Refresh Optive® (Purite) Refresh Optive®
CMC 0.5% Glycerin 0.9% Erythritol Sodium hyaluronate Refresh Repair® (Purite)
CMC 0.5% Glycerin1%
Polysorbate80 0.5% Erythritol L-Carnitine Castor oil Refresh Optive advanced
® (Purite) Refresh Optive advanced®
CMC 0.5% Glycerin 1%
Polysorbate80 0.5%
Erythritol L-Carnitine Trehalose
Castor oil Flaxseed oil Refresh Optive Mega-3
®
CMC 1% Refresh Liquigel® (Purite), Refresh Celluvisc
®,
Thera tears Liquigel®
CMC 1% Glycerin 0.9% Erythritol L-Carnitine Refresh Optive Gel® (Purite)
Table 2. Artificial tears containing hypromellose and dextran as demulcents.
Active Ingredient(s) Brand
Hypromellose 0.3% Dextran 0.1% GenTeal Mild® (Polyquaternium-1)
Hypromellose 0.3% Dextran 0.1% Glycerin 0.2% GenTeal Moderate
® (Polyquaternium-1) Also available as
preservative free
Hypromellose 0.3% + Carbopol 980
Hypromellose 0.3%
GenTeal Severe®,
Systane lubricant eye gel® (Sodium perborate)
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Table 3. Artificial tears containing propylene glycol, polyethylene glycol, and glycerin as demulcents.
Active Ingredient(s) Inactive Ingredients with
Biological Activity
Brand





















Glycerin 0.22–0.25% Sodium hyaluronate Oasis tears
®
Oasis tears plus®
Polyethylene Glycol 0.25% Sodium hyaluronate Blink Tears Blink Gel Tears
®
(Sodium Chlorite) Blink Tears
®
Glycerin 0.6%
Propylene Glycol 0.6% Soothe
®
Table 4. Artificial tears containing povidone and polyvinyl alcohol as demulcents.
Active Ingredient(s)
Brand
With Preservative Preservative Free
Povidone 1.25% Soothe Hydration® (EDTA)
Povidone 2% Soothe maximum hydration® (Benzalkonium Chloride)
Polyvinyl alcohol 1.4% Akorn® artificial tears (Benzalkonium Chloride)
Povidone 0.6%
Polyvinyl alcohol 0.5% Murine
® tears (Benzalkonium Chloride)
Povidone 2%
Polyvinyl alcohol 2.7% FreshKote
®
Our screening shows that povidone is the primary demulcent in Soothe hydration®
and maximum hydration brand eye drops, while polyvinyl alcohol is the demulcent
in Akorn® artificial tears (Akorn, Lake Forest, IL, USA). Murine® tears and FreshKote®
(Eyevance Pharmaceuticals, Fort Worth, TX, USA) use a combination of povidone and
polyvinyl alcohol (Table 4).
3.2. Biologically Active Excipients in Artificial Tears
One downside of the FDA’s pre-approved monograph is that if a developer lists an
active ingredient that is not on the FDA monograph, they need to provide clinical data
proving the safety of its ophthalmic use in humans. Many pharmaceutical excipients and
food additives have been shown to provide therapeutic relief in dry eye disease. Although
these excipients and additives have ophthalmic therapeutic potential, the manufacturers
list them under inactive ingredients in artificial tears to avoid trials. Because of their notable
biological activity, health care providers need to be aware of these excipients and additives.
Therefore, we carefully reviewed the biologically active pharmaceutical excipients and
food additives present in these drops.
Our survey data shows that the currently marketed artificial tears use the following
biologically active pharmaceutical excipients and food additives: (a) Osmoprotectants: tre-
halose, erythritol, levocarnitine, (b) Humectants: sodium hyaluronate, (c) Hydroxypropyl
Guar gum, (d) Oils: flaxseed oil, castor oil, mineral oil.
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Osmoprotectants are agents that protect cells against hyperosmolar stress-mediated
injury. Since hyperosmolarity is one the characteristics of dry eye, osmoprotectants are
emerging ingredients of artificial tears. Levocarnitine (L-carnitine) is present in prokaryotic
and eukaryotic cells, including human corneal and conjunctival epithelia [11,12]. Erythritol
is polyol used as a low-calorie sweetener. In vitro studies using cultured human corneal
epithelial cells demonstrate that osmoprotectants are taken up by the dehydrated cells,
then restore volume and prevent protein denaturation [13,14]. Trehalose is a naturally
occurring disaccharide consisting of two alpha-glucose units joined by glucoside bond.
Trehalose has also been shown to protect corneal epithelial cells from desiccation and
high osmolarity [15–17]. Our data analysis demonstrated that erythritol, L-carnitine, and
trehalose are present in some Refresh® brand artificial tears, which contain CMC as the
main demulcent (Table 1).
Humectants are hygroscopic agents that facilitate the retention of water. Hyaluronic acid
is a high molecular weight naturally occurring glycosaminoglycan polysaccharide [18,19].
It is present in connective tissue, synovial fluid, and in the aqueous humor, and is vitre-
ous [18,19]. Hyaluronic acid acts as a humectant and can bind water multiple times the
amount of its weight. Sodium hyaluronate is a semisynthetic smaller molecular weight
sodium salt derivative of hyaluronic acid. Like hyaluronic acid, sodium hyaluronate
also acts as a humectant to provide additional hydration. Its mucoadhesive proper-
ties are proposed to increase the corneal residence time. Our data demonstrates that
sodium hyaluronate is present in three artificial tear formulations with CMC, glycerin, and
polyethylene glycol as demulcents (Tables 1 and 3). It is worthwhile to note that in many
artificial tears marketed in Europe and Asia (e.g., Hylo brand tears®, Vismed Multi®, Xailin
HA®, Thealoz Duo®, BLUyal OSD®, Hyalistil Bio®, Artelac® Splash™, Zolag®), sodium
hyaluronate is listed as an active ingredient, because unlike the FDA, agencies in these
countries do not have a list of demulcents for expediated approval.
Hydroxypropyl guar is a viscous protein polymer derived from beans. Upon instilla-
tion, hydroxypropyl guar forms a soft gel with increased viscosity at the tear pH. It mimics
the properties of mucin layer by strengthening the attachment of the aqueous layer to the
mucins and promotes the retention of other demulcents [20,21]. It has also been shown to
stabilize the tear film. Hydroxypropyl guar is present in all Systane® brand artificial tears
(Table 3).
Flaxseed oil, castor oil, and mineral oil mimic the lipid layer of tear film, stabilize
tear film, increase lipid layer thickness, and prevent evaporation [22–24]. Our survey
demonstrates that among the currently marketed artificial tears, two Refresh brand for-
mulations contain castor oil, flaxseed oil, and polysorbate 80 with CMC as a demulcent
(Table 1). Two Systane® brand formulations contain mineral oil and phospholipid dimyris-
toyl phosphatidylglycerol with propylene glycol as demulcent (Table 3). Polysorbate 80
and dimyristoyl phosphatidylglycerol in these formulations act as emulsifiers in these
formulations, but also have additional biological advantage to help spread and stabilize
the lipid layer upon instillation [10]. All these oils containing artificial tear formulations
are emulsions.
3.3. Preservatives in Artificial Tears
Ophthalmic formulations are required to be sterile for the obvious reason of pro-
tecting the eye from infections. To maintain the sterility, artificial tears as a multidose
ophthalmic formulation need to contain preservatives or alternatively need to be packaged
as preservative-free single dose units. Based on our survey, the currently marketed arti-
ficial tears use purite, polyquaternium-1, sodium perborate, and benzalkonium chloride
as preservatives with only one brand Blink® Tears using sodium chlorite (Tables 1–4).
Many of these drops are also available in preservative-free single dose units. Refresh®
brand of tears contains purite as a preservative in their formulation but also offer most
of their tears in a preservative-free form (Table 1). Sodium perborate is the preservative
in Thera Tears® and GenTeal® brand tears (Tables 1 and 2). Polyquaternium (Polyquad)
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is the preservative present in GenTeal® and Systane® brand tears. All the artificial tears
with povidone and polyvinyl alcohol use benzalkonium chloride as a preservative except
FreshKote® which is available preservative-free (Table 4). Interestingly, Europe has many
artificial tears available in multidose special ophthalmic dispensers. These multidose
artificial tears are preservative-free, since the special dispensers are designed to prevent
microbial contamination.
4. Discussion
Demulcents are the primary active ingredient for artificial tears. Our data analysis
shows that there are primarily four categories of artificial tears to select from based on the
demulcent present in them. Two brands contain CMC as demulcents, with Thera Tears®
containing the lowest concentration of CMC at 0.25%. These drops are a great option for
patients with milder symptoms of dry eye who better tolerate lower concentrations of
CMC. Thera Tears® are available in multidose vial containing the vanishing preservative
sodium perborate or as preservative-free single application. Thera Tears extra® with 0.25%
CMC plus trehalose as an additional ingredient are available only as sodium perborate
preservative containing multidose vial. Sodium perborate, also known as Dequest, is a
vanishing type of preservative. In solution, it is converted to hydrogen peroxide and causes
the bactericidal effect by oxidative stress-mediated denaturation of bacterial proteins. Upon
instillation into an eye, it is converted to oxygen and water by the enzyme catalase. Sodium
perborate is less toxic than benzalkonium chloride but not completely innocuous [25,26].
Therefore, preservative-free Thera Tears® should be preferred if a patient needs more than
four applications per day.
Refresh® brand of artificial tears have several formulations containing 0.5% CMC
alone, with additional demulcents and biologically active excipients like osmoprotectants
erythritol, l-carnitine, and trehalose. L-carnitine and erythritol have been shown to attenu-
ate hyperosmolar stress-mediated increase in MAP kinases, pro-inflammatory cytokines,
and matrix metalloproteases in corneal epithelial cells [27–30]. Clinical studies demonstrate
that artificial tears containing L-carnitine and erythritol reduce tear osmolarity and provide
symptomatic relief [31–33]. Studies in animal models of dry eye and clinical studies with
trehalose containing eye drops demonstrate many beneficial effects, including increased
tear production, tear stabilization, reduced corneal staining, and a decrease in corneal
epithelial cell apoptosis [34–37]. Humectant sodium hyaluronate in Refresh®, Oasis® and
Blink® tears can offer significant additional relief in dry eye in preventing or treating corneal
epithelial damage since in vitro studies demonstrate that sodium hyaluronate promotes
corneal epithelial cell migration and proliferation, thus facilitating healing [38–40]. Topical
application of sodium hyaluronate in rabbits and mice has been shown to promote wound
healing and relieve dry eye symptoms [41,42]. Castor oils and flaxseed oil in some Refresh®
Brand tears will offer the additional benefit of reduced tear evaporation in patients with
evaporative dry eye. Purite, the preservative present in Refresh® brand artificial tears, is
stabilized oxychloro complex (SOC) containing 99.5% chlorite, 0.5% chlorate. In solution,
its bactericidal action is mediated by the oxidizing action of chlorine dioxide free radical.
It belongs to the vanishing class of artificial tears since upon instillation, it is converted
to sodium chloride, oxygen, and water [43,44]. Animal studies demonstrate that purite
is significantly less toxic to corneal epithelium compared to benzalkonium chloride but
has some degree of detrimental effect compared to preservative-free artificial tears [43–47].
Given the wide variety of options, a patient can be started on Refresh® tears with CMC
alone either with or without preservatives depending upon the frequency of instillation
required and if the dry eye relief is inadequate, Refresh® tears with additional biologically
active excipients can be tried.
The Systane® brand of tears use propylene glycol and glycerin as demulcent and
humectants to retain moisture at ocular surfaces along with dimyristol phosphatidyl
glycerol, hydroxy propyl guar, and mineral oil listed under inactive ingredients purportedly
mimicking the mucin and the lipid component of tear film and polyquaternium-1 as a
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preservative. In an in vitro model of 3D corneal epithelium, the dual polymer formulation
of hydroxypropyl guar/sodium hyaluronate demonstrated enhanced the ocular surface
hydration, surface retention, cell barrier function, and lubricity compared to single-polymer
formulations [19,20]. Polyquaternium (Polyquad) is a commonly used preservative in
Systane® ophthalmic drops. This compound is a quaternary ammonium compound and has
bactericidal activity due to the surfactant action just like benzalkonium chloride. However,
this compound is a large size polymer and is safe for mammalian cells, apparently due to
its reduced penetration owing to its larger size [43,48]. Several in vitro and animal studies
have compared the ocular surface toxicity of polyquaternium and benzalkonium chloride.
In vitro studies demonstrate that polyquaternium has low cytotoxicity and it is remarkably
safer than benzalkonium chloride [49–52]. Further, it seems to be well tolerated upon
topical instillation in animal studies and in patients taking polyquaternium preserved
glaucoma drops [53–56].
Benzalkonium chloride is another common preservative used in ophthalmic drops.
However, our data reveals that among the current brand name artificial tears, only Soothe®,
Akron®, and Murine® brand tears use benzalkonium chloride as a preservative. Benza-
lkonium chloride is an amphiphilic quaternary ammonium compound that kills bacteria
by surfactant action on their plasma membrane. However, mammalian cells, including
the corneal and conjunctival epithelial cells can also be impacted by the surfactant action
of benzalkonium chloride. In vitro studies using corneal and conjunctival epithelial cells
demonstrate that benzalkonium chloride decreases ocular surface epithelial cell viability
and increases the release of pro-inflammatory mediators [57–61]. Topical application of
benzalkonium chloride in rabbits and rodents has been demonstrated to cause tear film
abnormalities, reduction in mucins and goblet cell density, corneal epithelial desquamation,
and an influx of inflammatory cells [62–66]. Further studies in rodents revealed detrimental
changes in corneal innervation after topical application of benzalkonium chloride [67,68].
Glaucoma patients using benzalkonium chloride-containing eye drops have been reported
to suffer from reduced tear film and tear breakup time, as well as increased tear osmolar-
ity [43,69]. As observed in the animal studies, prolonged use of benzalkonium chloride
containing eye drops in glaucoma patients has also been shown to cause damage to the
ocular surface epithelial cells and corneal nerves [43]. Since many of the observed toxic
effects of benzalkonium chloride can exacerbate ocular surface damage and further worsen
the inflammatory response, the current consensus is to avoid the use of benzalkonium
chloride containing artificial tears in dry eye patients.
5. Conclusions
The goal of screening the marketed artificial tear formulations was to give health
care providers a formulary of artificial tears classified based on their active ingredients
and biologically active excipients. The options of preservative-free single dose units, if
available, has also been included in our data tables. The compiled information should assist
the healthcare providers to make a stepwise and rational selection of appropriate artificial
tears for the patients based on the active ingredients and biologically active excipients.
Due to the multifactorial etiology of dry eye, it is challenging to make generalized
recommendations about selecting appropriate artificial tears. However, based on recent
studies and clinical experience, some broad suggestions are available to make a judicious
selection [37,70–75]. Individualized artificial tear therapy needs to be based on patient’s
history, ocular examination, and clinical testing. Patients having mild increase in tear osmo-
larity and normal tear break up time (TBUT) can be managed with artificial tears containing
one or two demulcents such as CMC (Thera Tears®; Refresh Tears®), hypromellose plus
dextran (GenTeal Mild®), or polyols (Soothe®, Systane Original®, Systane Ultra®). Thera
tears are hypo-osmolar and have a slightly alkaline pH that may offer a more soothing
effect for some patients. If monitoring reveals inadequate response, formulation with
added excipients such as osmoprotectants and sodium hyaluronate can be tried (Thera
Tears Extra®, Refresh Optive®, Refresh Repair®, Oasis®, Blink Tears®). Awareness about
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artificial tears based on different demulcents as active ingredients can help one make a
rational switch from one class of active ingredient to another class in the case of inadequate
relief. Cases with a moderate increase in osmolarity and quick TBUT may denote significant
evaporative dry eye. Dry eye due to meibomian gland dysfunction also has significant
evaporative component due to deficiency in the lipid layer. In such cases, artificial tears
that contain lipid components including castor oil (Refresh Optive Advance®), flaxseed oil
(Refresh Optive Omega 3®), mineral oil, and dimyristoyl phosphatidyl glycerol (Systane
Balance®, Systane Complete®) that either replenish or stabilize the lipid layer should be
considered. Formulations with unique bioactive excipients, such as dimyristoyl phos-
phatidyl glycerol and hydroxypropyl guar, may work better for some patients (Systane
Original®, Systane Ultra®, Systane Balance®, Systane Complete®). The awareness about
the availability of preservative-free formulations in each category is also critical. The option
should be discussed with the patient whether they can afford preservative-free artificial
tears and are willing to try them. Preservative-free formulations are recommended for
patients requiring more than four to six applications per day.
Cases with moderate to high increase in osmolarity and significant ocular surface
staining invariably require prescription based anti-inflammatory drops. The importance of
lifestyle and dietary modification should be emphasized during counseling and is helpful
for all types of dry eye patients. Warm compresses and lid hygiene are also critical for
meibomian gland dysfunction. Use of gels and nighttime ointments is also an option for
moderate cases. Ointments are exclusively for nighttime use but some gel formulations
(Refresh Liquigel®, Refresh Celluvisc®, Refresh Optive Gel®, Systane Gel Drops®, Blink
Gel Tears®) can be used during both the day and nighttime. Patients need to be counselled
on transient blurring of vision with the daytime use of gels.
Several clinical studies have tested the efficacy of artificial tears in patients suffering
from dry eye. These trials have been extensively reviewed [37,70–75]. Although no
conclusive recommendations demonstrate the efficacy of one class of artificial tears is
superior over another class due to variability in the study design, tested clinical end points,
patients’ heterogeneity, and sponsor bias [70,71], nonetheless, these trials consistently
demonstrate that artificial tears show therapeutic benefits and are useful armaments in the
management of dry eye.
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